UBS AM
CLLS

UBS AM’s Cellectis CLLS Stock Holding History

UBS AM’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.93M Sell
2,644,881
-533,739
-17% -$1.9M ﹤0.01% 1378
2026
Q1 		$10.1M Hold
3,178,620
– – ﹤0.01% 1185
2025
Q4 		$15.4M Buy
+3,178,620
New +$13.3M ﹤0.01% 947
2025
Q3 		– Sell
-3,178,620
Closed -$4.85M – 2350
2025
Q2 		$4.85M Sell
3,178,620
-1,544,044
-33% -$2.23M ﹤0.01% 1722
2025
Q1 		$5.86M Buy
4,722,664
+3,284,409
+228% +$4.87M ﹤0.01% 1491
2024
Q4 		$2.59M Hold
1,438,255
– – ﹤0.01% 1918
2024
Q3 		$3.05M Hold
1,438,255
– – ﹤0.01% 1814
2024
Q2 		$2.69M Buy
+1,438,255
New +$3.77M ﹤0.01% 1835

Other funds holding CLLS

BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
DRD
Dennis R. Delaney $314M AUM 35.76% 1-Year Est. Return

UBS AM's CLLS Position: Q2 2026 in Review

UBS AM reduced its Cellectis (CLLS) stake by 17% in Q2 2026, selling an estimated $1.9M and leaving 2,644,881 shares worth $7.93M. The position accounts for ﹤0.01% of the portfolio, ranked #1378.

UBS AM first reported a position in CLLS in Q2 2024 and has held it in 8 quarters since. The position peaked at $15.4M in Q4 2025. 27 funds tracked by Wall St. Rank hold CLLS as of Q2 2026.

  • UBS AM held 2,644,881 shares of Cellectis worth $7.93M as of Q2 2026.
  • UBS AM sold 533,739 Cellectis shares in Q2 2026, an estimated $1.9M.
  • Cellectis made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1378 holding.
  • UBS AM first reported a position in Cellectis in Q2 2024 and has held it in 8 quarters since.
  • UBS AM's Cellectis position peaked at $15.4M in Q4 2025.
  • 27 funds tracked by Wall St. Rank held Cellectis as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.